S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Arcellx (ACLX) Stock Price, News & Analysis

$51.65
-2.85 (-5.23%)
(As of 04/19/2024 ET)
Today's Range
$51.03
$54.80
50-Day Range
$51.65
$73.49
52-Week Range
$30.74
$75.10
Volume
742,727 shs
Average Volume
453,949 shs
Market Capitalization
$2.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.17

Arcellx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
43.6% Upside
$74.17 Price Target
Short Interest
Bearish
9.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of Arcellx in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$42.44 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.69) to ($1.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.46 out of 5 stars

Medical Sector

468th out of 911 stocks

Biological Products, Except Diagnostic Industry

69th out of 150 stocks

ACLX stock logo

About Arcellx Stock (NASDAQ:ACLX)

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

ACLX Stock Price History

ACLX Stock News Headlines

Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
ACLX Apr 2024 70.000 call
William Blair Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
See More Headlines
Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/19/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ACLX
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$74.17
High Stock Price Target
$87.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+40.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-70,690,000.00
Pretax Margin
-63.48%

Debt

Sales & Book Value

Annual Sales
$110.32 million
Book Value
$9.97 per share

Miscellaneous

Free Float
50,167,000
Market Cap
$2.82 billion
Optionable
Optionable
Beta
0.02
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives


ACLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings
or view top-rated stocks.

What is Arcellx's stock price target for 2024?

12 analysts have issued 12-month price targets for Arcellx's shares. Their ACLX share price targets range from $50.00 to $87.00. On average, they expect the company's share price to reach $74.17 in the next year. This suggests a possible upside of 43.6% from the stock's current price.
View analysts price targets for ACLX
or view top-rated stocks among Wall Street analysts.

How have ACLX shares performed in 2024?

Arcellx's stock was trading at $55.50 on January 1st, 2024. Since then, ACLX shares have decreased by 6.9% and is now trading at $51.65.
View the best growth stocks for 2024 here
.

When is Arcellx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ACLX earnings forecast
.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) posted its quarterly earnings data on Wednesday, February, 28th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.95. The business earned $63.15 million during the quarter, compared to the consensus estimate of $20.07 million. Arcellx had a negative trailing twelve-month return on equity of 20.96% and a negative net margin of 64.08%. During the same period last year, the company earned ($0.76) EPS.

What ETFs hold Arcellx's stock?

ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Principal Healthcare Innovators ETF (BTEC).

When did Arcellx IPO?

Arcellx (ACLX) raised $132 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 8,250,000 shares at a price of $15.00-$17.00 per share.

Who are Arcellx's major shareholders?

Arcellx's stock is owned by many different retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.04%), Allspring Global Investments Holdings LLC (0.02%) and High Net Worth Advisory Group LLC (0.02%). Insiders that own company stock include Christopher Heery, Enterprise Associates 15 New, Jill Carroll, Michelle Gilson, Olivia C Ware, Rami Elghandour, Scott D Sandell and Sr One Capital Management, Llc.
View institutional ownership trends
.

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACLX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners